My watch list
my.bionity.com  
Login  

Novartis settles patent litigation on Gleevec with Sun Pharma subsidiary

16-May-2014

Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec® (imatinib mesylate), which expire in 2019 (including pediatric exclusivity). The basic compound patent for Gleevec expires in the U.S. on July 4, 2015.

As a result of the settlement, Novartis will permit Sun Pharma's subsidiary to market a generic version of Gleevec in the United States on February 1, 2016. The terms of the settlement agreement are otherwise confidential. Sun Pharma's subsidiary has received tentative approval from the US Food and Drug Administration (FDA) for its generic version of imatinib mesylate.

Facts, background information, dossiers
  • imatinib
More about Novartis
More about Sun Pharmaceutical Industries
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE